New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareChonluten vs Palmitoyl Tetrapeptide-7

Chonluten vs Palmitoyl Tetrapeptide-7

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Chonluten
Skin & Cosmetic
Palmitoyl Tetrapeptide-7
Summary
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
Palmitoyl Tetrapeptide-7 (Rigin) is a cosmetic peptide consisting of palmitic acid linked to the tetrapeptide sequence GQPR (Gly-Gln-Pro-Arg). It was designed to mimic the biological activity of the IgG immunoglobulin C-terminus, which downregulates the production of interleukin-6 (IL-6), a key driver of skin aging and inflammation.
Half-Life
Short (minutes for the peptide); sustained gene-regulatory effects
Topical penetration-dependent; effects last hours to days
Admin Route
SubQ, Oral
Topical
Research
Typical Dose
10 mg per day
2-5 ppm concentration in formulation
Frequency
Daily for 10–30 days
Twice daily
Key Benefits
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
  • Reduces IL-6 inflammatory cytokine in skin
  • Prevents 'inflammaging' of the skin
  • Inhibits MMP collagen-degrading enzymes
  • Synergistic with Matrixyl for anti-aging
  • Clinically tested for wrinkle and skin texture improvement
  • Well-tolerated topically
Side Effects
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
  • Contact sensitization (rare)
  • Well-tolerated at standard concentrations
Stacks With